iBio (IBIO) Net Cash Flow (2010 - 2026)

iBio (IBIO) has 17 years of Net Cash Flow data on file, last reported at $18.9 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 1023.6% year-over-year to $18.9 million in Q1 2026; TTM through Mar 2026 was $42.7 million, a 3487.46% increase from a year earlier, with the FY2025 full-year figure at -$5.6 million, down 182.22% from the prior year.
• Net Cash Flow for Q1 2026 stood at $18.9 million, up from $567000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for IBIO reached as high as $19.5 million in Q3 2025 and fell as low as -$12.8 million in Q3 2022.
• Historically, Net Cash Flow has averaged $157352.9 across 5 years, with a median of -$2.1 million in 2025.
• Across the five-year window, Net Cash Flow sank 476.18% in 2024 and soared 1023.6% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$11.9 million in 2022, then surged by 94.13% to -$701000.0 in 2023, then sank by 476.18% to -$4.0 million in 2024, then jumped by 114.04% to $567000.0 in 2025, then surged by 3240.92% to $18.9 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $18.9 million in Q1 2026, $567000.0 in Q4 2025, and $19.5 million in Q3 2025.